Physician profile
Patrick P Lo
NPI 1295742039
$3,080.51
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $341 · 2020: $960 · 2021: $1,397 · 2022: $327 · 2023: $12.92 · 2024: $44.10.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $57.02.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $57.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $406.61 | 2020-2022 | |
| Novo Nordisk INC | $360.19 | 2020-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $334.66 | 2019-2022 | |
| Astrazeneca Pharmaceuticals Lp | $300.02 | 2019-2021 | |
| Glaxosmithkline, LLC. | $270.43 | 2019-2022 | |
| Amarin Pharma, INC. | $236.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $190.10 | 2019-2024 | Gardasil, Gardasil 9 |
| Astellas Pharma US INC | $179.99 | 2021-2022 | |
| Sunovion Pharmaceuticals INC. | $117.14 | 2019-2022 | |
| Gilead Sciences, INC. | $112.80 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $97.12 | 2019-2020 | |
| Lilly USA, LLC | $73.01 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $72.46 | 2021 | |
| Esperion Therapeutics, INC. | $57.16 | 2020-2021 | |
| Amgen INC. | $53.75 | 2021-2022 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $28.24 | 2024 | Monoferric |
| Biogen, INC. | $21.77 | 2021 | |
| Abbott Laboratories | $20.79 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.06 | 2020 | |
| Abbvie INC. | $18.19 | 2021 | |
| Ascend Therapeutics US, LLC | $18.00 | 2021 | |
| Sanofi Pasteur INC. | $15.98 | 2022 | |
| Celgene Corporation | $13.43 | 2019 | |
| Corium, LLC | $12.92 | 2023 | Adlarity |
| Scynexis, INC. | $12.72 | 2022 | |
| Eisai INC. | $12.70 | 2021 | |
| Scilex Pharmaceuticals INC. | $12.58 | 2021 | |
| Zyla Life Sciences, INC. | $11.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Lo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.